Sucampo's Lubiprostone effective in children and adolescents


Sucampo Pharmaceuticals' (SCMP) Lubiprostone treatment was effective and well tolerated in a trial of 127 of children and adolescents with functional constipation.

"The results of this study support lubiprostone's potential to become the first prescription treatment option available for children suffering from constipation," says Sucampo CEO Ryuji Ueno.

Sucampo now intends to initiate two Phase 3 trials of Lubiprostone. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs